A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Virus Infection

Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2009
This article has no abstract
Epistemonikos ID: b746b34e204b48ee070be3504db1e78ff7f966f9
First added on: Apr 16, 2025